Leflunomide is an FDA-approved drug for the treatment of rheumatoid arthritis, and its pharmacological role is to activate Mfn2-mediated mitochondrial fusion by inhibiting dihydroorotate dehydrogenase (DHODH) (120). The gene discussed is DHODH; the disease is rheumatoid arthritis.